Literature DB >> 1277216

Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.

G Voelcker, T Wagner, H J Hohorst.   

Abstract

The existence of the cyclophosphamide (CP) metabolites, 4-hydroxycyclophosphamide and aldophosphamide, in vivo after application of CP to mice and rats has been demonstrated. The metabolite pattern in the serum and urine of rats at different times after CP application was determined. For this purpose, thin-layer chromatograpic procedure was developed which allows separation of the metabolites without decomposition. Because considerable amounts of radioactivity are bound to serum proteins after 3H-CP application, protein binding studies with CP and CP metabolites were carried out. It was found that 4-hydroxycyclophosphamide is bound to thiol groups of bovine serum albumin yielding a rather stable product which could be isolated by column chromatography on Sephadex.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277216

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  9 in total

1.  [On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)].

Authors:  G Voelcker; H P Giera; L Jäger; H J Hohorst
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-05-31

Review 2.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

3.  Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites.

Authors:  U Schuler; G Ehninger; T Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.

Authors:  Fei Li; Andrew D Patterson; Constance C Höfer; Kristopher W Krausz; Frank J Gonzalez; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2010-06-10       Impact factor: 5.858

Review 5.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

6.  Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model.

Authors:  Lena E Friberg; Marie Sandström; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2009-08-27       Impact factor: 3.850

7.  [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].

Authors:  T Wagner; D Heydrich; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1980-01       Impact factor: 4.553

8.  Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents.

Authors:  H H Gerhartz; E Liss; H Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1979-07-27       Impact factor: 4.553

9.  Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse.

Authors:  D S Alberts; Y M Peng; H S Chen; R F Struck
Journal:  Br J Cancer       Date:  1978-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.